GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » Short Percentage of Float

TME Pharma NV (XPAR:ALTME) Short Percentage of Float


View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of TME Pharma NV's Short Percentage of Float

For the Biotechnology subindustry, TME Pharma NV's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TME Pharma NV's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's Short Percentage of Float falls into.


TME Pharma NV (XPAR:ALTME) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » Short Percentage of Float
Comparable Companies
XPAR:ALQGC XPAR:ALMDP XPAR:ALNEV XPAR:ALBPS XPAR:ALPHA XPAR:ALVET XPAR:ALINT XPAR:ALPAT XPAR:ALTHX XPAR:ALNFL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0N6A:Germany
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
Website
https://www.tmepharma.com
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines